Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
dHER2+AS15 ASCI with Lapatinib in HER2+ Metastatic Breast Cancer
NCT00952692Phase 2Completed
- Sponsor
- Michael Morse
- Start
- Jul 2009
- Primary completion
- Jul 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dHER2 + AS15 in breast cancer, sponsored by Michael Morse. Primary endpoints: Occurrence of Severe Toxicities at 26 weeks and Number of Participants With T-cell Response at 26 weeks. Started Jul 2009; status: completed.
02
Drugs
dHER2 + AS15
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00952692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00952692.